Ocular Therapeutix, Inc. (OCUL) Longs: Don’t Rock the Boardroom Too Much!

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is on recovery track with 12.68% gain from a 1-year low price of $3.55. The company lost -3.61% to attain the price of $4 on 01/10/2019. Throughout the recent session, the prices were hovering between $3.92 and $4.1787. These shares are 260.75% off its target price of $14.43 and the current market capitalization stands at $156.4M. The recent change has given its price a -21.38% deficit over SMA 50 and -51.67% deficit over its 52-week high. The stock witnessed -28.57% declines, -35.79% declines and -38.65% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found OCUL’s volatility during a week at 7.18% and during a month it has been found around 8.73%.

Ocular Therapeutix, Inc. (OCUL) Top Holders

Institutional investors currently hold around $90 million or 52.7% in OCUL stock. Look at its top three institutional owners. Summer Road Llc owns $12.56 million in Ocular Therapeutix, Inc., which represents roughly 8.03% of the company’s market cap and approximately 13.96% of the institutional ownership. Similar statistics are true for the second largest owner, Jennison Associates Llc, which owns 2,335,989 shares of the stock are valued at $9.69 million. The third largest holder is Fmr Llc, which currently holds $9.55 million worth of this stock and that ownership represents nearly 6.1% of its market capitalization.

Ocular Therapeutix, Inc. 13F Filings

At the end of September reporting period, 37 institutional holders increased their position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by some 1,903,854 shares, 25 decreased positions by 2,057,057 and 19 held positions by 17,746,138. That puts total institutional holdings at 21,707,049 shares, according to SEC filings. The stock grabbed 14 new institutional investments totaling 886,887 shares while 9 institutional investors sold out their entire positions totaling 101,505 shares.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Trades

Multiple company employees have indulged in significant insider trading. Ocular Therapeutix, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Hanley Kevin F. has acquired 10,000 shares of Ocular Therapeutix, Inc. (OCUL) in trading session dated Dec. 14, 2018. These shares are worth $55,000 and were traded at $5.5 each. The SEC filing shows that Hanley Kevin F. performed a purchase of 10,000 shares. The added these shares by way of transaction on Dec. 10, 2018. The company’s shares were assimilated at $5.6 per share worth to an investment of some $56,000 on account of Hanley Kevin F..

Bollag Daniel M, purchased 17,400 common shares of Ocular Therapeutix, Inc. (OCUL) in the open market. In a transaction dated Dec. 06, 2018, the shares were bought at an average price of $5.76, giving away a sum of $100,224. After this purchase, 42,100 common shares of OCUL are directly owned by the insider, with total stake valued at $168,400.

In the transaction dated Aug. 20, 2018, the great number of shares acquired came courtesy the President & CEO; Mattessich Antony C. added a total of 20,000 shares at an average price of $5.95, amounting to approximately $119,000. The insider now directly owns 57,900 shares worth $231,600.

Ocular Therapeutix, Inc. (OCUL) Analyst Guide

Several analysts have released their opinion on Ocular Therapeutix, Inc. (NASDAQ:OCUL), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.71 average brokerage recommendation.